The structural profiles are close, with Alnylam Pharmaceuticals carrying a narrow edge on growth. UCB still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, UCB carries the stronger setup — intact trend against Alnylam Pharmaceuticals's broken trend. That leaves a split case: the structural lead stays with Alnylam Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ALNY: Nasdaq 100, UCB.BR: STOXX 600).
This is not just a one-metric split: both growth and profitability materially support the lead.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and UCB.BR share the same industry classification.
For a similarity-based comparison, see how Alnylam Pharmaceuticals and UCB each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Alnylam Pharmaceuticals, Inc. still looks stronger overall, though current pricing looks more supportive for UCB SA.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ALNY and UCB.BR each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.
Absolute pricing still looks more supportive for UCB, with a forward P/E that is 3.9 turns lower there.
The lead is built on both growth and profitability — though valuation still provides a counterweight.
Break down the ALNY vs UCB.BR comparison across all dimensions with the full interactive tool.
Explore how ALNY and UCB.BR each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.